Burlington, MA–based Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures, along with additional funding from existing backers ARCH Ventures, 5AM Ventures and Atlas Venture, bringing the company’s total capital raised to $112 million. The investment comes as the clinical-stage biotech prepares to report its first human data for LFD-200, a VISTA-targeted antibody-drug conjugate designed to deliver glucocorticoids directly to immune cells while avoiding systemic steroid toxicity.
The company is currently dosing healthy volunteers in a phase 1 trial, with safety and pharmacodynamic readouts expected by year end. Patient studies in moderate to severe rheumatoid arthritis are planned to follow pending the healthy volunteer data.
For Sanofi Ventures, the investment signals confidence in Lifordi’s approach to a problem that has constrained steroid therapy for three quarters of a century: separating anti-inflammatory efficacy from the metabolic, bone and endocrine toxicity that limits long term glucocorticoid use.
Proof of concept already exists
Lifordi is not the first to attempt targeted glucocorticoid delivery, and that precedent is both encouraging and cautionary for investors watching LFD-200’s clinical progress.
AbbVie’s ABBV-3373, an anti-TNF ADC carrying a proprietary glucocorticoid receptor modulator payload, provided early validation of the concept. In a phase 2a study in rheumatoid arthritis patients, ABBV-3373 improved disease activity scores more than adalimumab alone while serial cortisol measurements over 12 weeks suggested minimal systemic steroid exposure. The data effectively proved that an ADC could deliver a steroid payload into activated immune cells and spare the hypothalamic-pituitary-adrenal axis.
Yet despite encouraging efficacy and a clean cortisol signal, ABBV-3373 did not rapidly advance toward registration. At least one serious anaphylactic reaction has been reported in connection with the program, and it no longer features prominently in AbbVie’s near-term RA pipeline disclosures.
Similarly, pegylated liposomal prednisolone (Nanocort) outperformed depot methylprednisolone in RA flares but encountered complement activation-related pseudoallergy (CARPA) that limited adoption.
In essence, the pharmacology works, but hypersensitivity and immunogenicity remain critical gating factors. For LFD-200, the differentiating question is whether a VISTA-targeted vehicle delivered subcutaneously can avoid the safety liabilities that stalled prior programs.
VISTA as delivery vehicle,
LFD-200 is built around a specific biological rationale rather than generic immune-cell targeting. VISTA (V-domain Ig suppressor of T cell activation) is highly expressed on synovial macrophages and neutrophils in the RA joint, the same cell types that drive local cytokine production and joint destruction.
Lifordi’s approach uses VISTA as a mailbox rather than a therapeutic target. According to preclinical data the company presented at ACR 2025, the LFD-200 antibody rapidly internalizes after binding VISTA, carrying the conjugated glucocorticoid payload into immune cells while limiting exposure in bone, liver, and the adrenal axis. In 13-week nonclinical studies, weekly subcutaneous dosing maintained glucocorticoid levels inside immune cells without detectable systemic steroid toxicity.
The biology carries some mechanistic risk. VISTA is a negative immune checkpoint, and blocking it can alter macrophage gene expression. Lifordi’s hypothesis is that very rapid internalization minimizes the window during which the antibody might interfere with VISTA signaling at the cell surface. Early clinical pharmacodynamic data will be key to confirm whether LFD-200 functions primarily as a delivery vehicle rather than as an immunologic modulator in its own right.
What early data need to show
The investment comes as Lifordi prepares to generate data that will determine whether LFD-200 can fill a gap that current RA guidelines acknowledge but have not closed. Modern treatment recommendations emphasize minimizing chronic glucocorticoid use because of well-documented metabolic and skeletal risks. In practice, however, glucocorticoid bridging remains common as patients wait the 6 to 12 weeks required for conventional or biologic DMARDs to reach full efficacy.
For clinicians to adopt LFD-200, the drug will need to match the rapid onset of oral prednisone while demonstrating a safety profile that clearly diverges from systemic steroid patterns. By concentrating glucocorticoid exposure inside immune cells, LFD-200 also shifts the toxicity question from classical systemic effects toward intracellular failure modes. Long-term glucocorticoid exposure can induce glucocorticoid receptor resistance in macrophages and can upregulate PD-1 expression on T cells, creating an exhaustion-like phenotype.
Filed Under: Rheumatology
